AAPGV - Dhuwit awis perusahaan Ascentage

Ascentage Pharma Group Ltd (AAPGV) - logo korporat

Strong confidence among hematologists in targeted developments has established a solid reputational foundation for Ascentage Pharma Group (AAPGV). Cash volume dynamics demonstrate current liquidity, where the parameter value reaches 0.16. Growth prospects are based on the licensing of small molecules to combat viruses and cancer, as well as the implementation of a unique platform designed to block tumor cell survival at the molecular level.

AAPGV - Volume dana dhuwit perusahaan Ascentage Pharma Group International ing rentang 25.01.2025 - 21.11.2026

Ringkesan rincian data analitis Ascentage Pharma Group Ltd (AAPGV)

Produk merek Ascentage Pharma Group International

This indicator provides a real-time assessment of highly liquid assets that react promptly to any cash flows. The metric determines the business's ability to cover current expenses and obligations without resorting to external debt capital. For Ascentage Pharma Group (AAPGV), maintaining a sufficient liquidity buffer is critical for supporting costly clinical trials of oncology drugs. Investors should evaluate the balance between financial stability and capital efficiency. Analyzing the cash volume chart allows for the timely identification of potential liquidity gaps.

Analisis pesaing Ascentage Pharma Group

Volume dana dhuwit perusahaan ONC|HALO - Cadangan dhuwit perusahaan|Revolution Medicines - Dhuwit awis perusahaan|Volume dana dhuwit perusahaan Ascentage Pharma AAPG|CGON - Dana dhuwit perusahaan|Total volume dana dhuwit perusahaan URGN|BCAX: Volume dana dhuwit perusahaan|PSNL - Aset likuid perusahaan|ERAS (Erasca Inc) - Volume dana dhuwit perusahaan|Cadangan dhuwit perusahaan Delcath Systems Inc DCTH|Dana dhuwit perusahaan YmAbs (YMAB)|Aset likuid perusahaan Aura Bio|Volume dana dhuwit perusahaan CADL (Candel Therapeutics Inc.)|accuray.com (ARAY) - Cadangan dhuwit perusahaan|SELLAS Life Sciences Group - Volume dana dhuwit perusahaan|ACTU - Volume dana dhuwit perusahaan|CTOR: Volume dana dhuwit perusahaan|Cadangan dhuwit perusahaan TuHURA (HURA)|TARA (Protara Therapeutics Inc) - Volume dana dhuwit perusahaan|Fate Therapeutics, Inc. (FATE) - Aset likuid perusahaan|Dhuwit awis perusahaan WHWK (Aadi Bioscience, Inc.)|Aset likuid perusahaan TScan Therapeutics, Inc.|Volume dana dhuwit perusahaan CSBR (Champions Oncology Corp)|Gunggung dana dhuwit perusahaan XBIT (XBiotech USA)|CVM - Dana dhuwit perusahaan|Sisa dhuwit perusahaan OSTX (ostherapies.com)|Radiopharm Theranostics Ltd (RADX) - Dana dhuwit perusahaan|ARTV: Gunggung dana dhuwit perusahaan|ANL (adlainortye.com) - Volume dana dhuwit perusahaan|VERU: Sisa dhuwit perusahaan|Dhuwit awis perusahaan TPST (Tempest Tx)|Dhuwit awis perusahaan Xilio XLO|Volume dana dhuwit perusahaan RENB (Renovaro)|Volume dana dhuwit perusahaan Mural Bio MURA|Kairos Pharma Ltd - Volume dana dhuwit perusahaan|OnKure Therapeutics (OKUR) - Dhuwit awis perusahaan|GDTC: Volume dana dhuwit perusahaan|Curis Inc. - Sisa dhuwit perusahaan|Dana dhuwit perusahaan apollomicsinc.com|THAR: Sisa dhuwit perusahaan|Dana dhuwit perusahaan Advanced Biomed Corp (ADVB)|GNPX (Genprex, Inc) - Sisa dhuwit perusahaan|Volume dana dhuwit perusahaan CLDI (Calidi Biotherapeutics)|sunshinebiopharma.com (SBFM) - Cadangan dhuwit perusahaan|Xenetic Bio - Volume dana dhuwit perusahaan|SLRX (Salarius Pharmaceuticals, Inc.) - Dhuwit awis lan setara dhuwit awis perusahaan|PPBT: Volume dana dhuwit perusahaan|Dhuwit awis perusahaan American Oncology Network Inc|BGNE (beigene.com) - Volume dana dhuwit perusahaan|Dhuwit awis lan setara dhuwit awis perusahaan CKPT (Checkpoint Therapeutics)|Dhuwit awis perusahaan ELEV (Elevation Oncology Inc.)|iCAD - Dhuwit awis lan setara dhuwit awis perusahaan|Ikena Oncology Inc. - Dhuwit awis perusahaan|Notable Labs Corp (NTBL) - Cadangan dhuwit perusahaan|VIRX: Dhuwit awis perusahaan|Cadangan dhuwit perusahaan morphosys.com|NAYA (NAYA Biosciences Corp) - Dhuwit awis perusahaan